Johnson & Johnson (JNJ)

$238.17 +1.17 (0.49%)
Market Cap 558.86B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.69
Forward PE 20.12
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 5,299,371
Avg Vol 7,616,270
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 96%
Beta 0.26
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Wallstfan
Wallstfan Jun. 10 at 7:30 PM
$AMZN Geeze I mine as sell and just buy $JNJ LOL. This thing could drop to that $205- 213 range soon
0 · Reply
Trader_Ty
Trader_Ty Jun. 10 at 4:23 PM
$JNJ bull flag breakout here
0 · Reply
option4kingjesus
option4kingjesus Jun. 10 at 4:12 PM
$JNJ are we bullish due to earings run up? follow for more info.
0 · Reply
focafoca99
focafoca99 Jun. 10 at 3:40 PM
$JNJ suffered a $32 million verdict in a Los Angeles asbestos trial. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-hit-with-6de303
1 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jun. 10 at 2:31 PM
SUPER HIGH CONFIDENCE 🚨 6/12 $JNJ 250c @.22 1000 CONTRACTS
0 · Reply
GTNew
GTNew Jun. 10 at 2:21 PM
$JNJ Trend line breakout
0 · Reply
flgoldpanther
flgoldpanther Jun. 10 at 2:19 PM
$JNJ How is this not trending ?
0 · Reply
Woodman7
Woodman7 Jun. 10 at 1:15 PM
$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news
0 · Reply
Quantumup
Quantumup Jun. 10 at 11:26 AM
BofA⬆️ $TYRA's PT to $42 (was $37), reiterated Buy and said: After a strong start to 2026, sentiment on Tyra has cooled despite seemingly little change to the story (since May: TYRA -25% vs. NBI flat). CGON URGN $JNJ ENGN IBRX $TARA Here's what BofA went on to say: https://x.com/Quantumup1/status/2064669900359016705?s=20
0 · Reply
TW_Research
TW_Research Jun. 10 at 11:01 AM
This is really a breast cancer story right now. GBM may end up getting some great news from the FDA but that's not why you should be investing in $KZIA . The base case scenario is we kick ass in TNBC, add on other breast indications, and start working our way towards a valuation like $CELC has. Upside from GBM would be wonderful but we'll still be worth billions without Jon Friend ever mentioning it again. BTW, did you see $JNJ bought Firefly Bio for $1B in CASH?! They have a preclinical degrader. Kazia has two of those programs. We are early innings here people...lots of runway in front of us. @futureexmillionare @ocellated
1 · Reply
Latest News on JNJ
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 4 hours ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 9 hours ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 1 day ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 1 day ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T13:00:56.000Z - 2 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

Johnson & Johnson to acquire Firefly Bio for $1B in cash

2026-06-08T12:14:56.000Z - 2 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 2 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 4 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:38:11.000Z - 7 days ago

Johnson & Johnson presents exploratory analyses from DAHLIAS study

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

2026-06-03T09:31:04.000Z - 7 days ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 7 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 7 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 7 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:41:49.000Z - 9 days ago

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

2026-05-31T21:40:07.000Z - 9 days ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 10 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 10 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 10 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 10 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 12 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

2026-05-29T12:49:22.000Z - 12 days ago

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 12 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 12 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 13 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 13 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 14 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 20 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 20 days ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 22 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 22 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 26 days ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 4 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 4 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 5 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026, 8:00 AM EDT - 5 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 5 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 5 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 6 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 6 weeks ago

J&J sees AI halving the time to generate drug development leads

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 27, 2026, 8:03 AM EDT - 6 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 24, 2026, 4:30 PM EDT - 6 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Cramer says look to these 4 stocks to go with your high-flying tech names

Apr 23, 2026, 6:44 PM EDT - 6 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: AGM 2026

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 8:05 AM EDT - 7 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 22, 2026, 4:00 AM EDT - 7 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 4:22 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 21, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 10:36 PM EDT - 7 weeks ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 7 weeks ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 4:11 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 2 months ago

Johnson & Johnson CFO on the company's robotic surgical system

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Apr 14, 2026, 10:30 AM EDT - 2 months ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Wallstfan
Wallstfan Jun. 10 at 7:30 PM
$AMZN Geeze I mine as sell and just buy $JNJ LOL. This thing could drop to that $205- 213 range soon
0 · Reply
Trader_Ty
Trader_Ty Jun. 10 at 4:23 PM
$JNJ bull flag breakout here
0 · Reply
option4kingjesus
option4kingjesus Jun. 10 at 4:12 PM
$JNJ are we bullish due to earings run up? follow for more info.
0 · Reply
focafoca99
focafoca99 Jun. 10 at 3:40 PM
$JNJ suffered a $32 million verdict in a Los Angeles asbestos trial. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-hit-with-6de303
1 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jun. 10 at 2:31 PM
SUPER HIGH CONFIDENCE 🚨 6/12 $JNJ 250c @.22 1000 CONTRACTS
0 · Reply
GTNew
GTNew Jun. 10 at 2:21 PM
$JNJ Trend line breakout
0 · Reply
flgoldpanther
flgoldpanther Jun. 10 at 2:19 PM
$JNJ How is this not trending ?
0 · Reply
Woodman7
Woodman7 Jun. 10 at 1:15 PM
$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news
0 · Reply
Quantumup
Quantumup Jun. 10 at 11:26 AM
BofA⬆️ $TYRA's PT to $42 (was $37), reiterated Buy and said: After a strong start to 2026, sentiment on Tyra has cooled despite seemingly little change to the story (since May: TYRA -25% vs. NBI flat). CGON URGN $JNJ ENGN IBRX $TARA Here's what BofA went on to say: https://x.com/Quantumup1/status/2064669900359016705?s=20
0 · Reply
TW_Research
TW_Research Jun. 10 at 11:01 AM
This is really a breast cancer story right now. GBM may end up getting some great news from the FDA but that's not why you should be investing in $KZIA . The base case scenario is we kick ass in TNBC, add on other breast indications, and start working our way towards a valuation like $CELC has. Upside from GBM would be wonderful but we'll still be worth billions without Jon Friend ever mentioning it again. BTW, did you see $JNJ bought Firefly Bio for $1B in CASH?! They have a preclinical degrader. Kazia has two of those programs. We are early innings here people...lots of runway in front of us. @futureexmillionare @ocellated
1 · Reply
cwEWF
cwEWF Jun. 10 at 9:52 AM
$JNJ favors rally to 259 or higher in daily from #bluebox area It is showing only 3 swing bounce from 5.11.2026 low and extend towards 236 - 245.4 area before pullback starts against 6.01.2026 low. Check before/after forecasts. #Elliottwave #JNJ
0 · Reply
flgoldpanther
flgoldpanther Jun. 9 at 8:05 PM
$JNJ Money rotation/ flowing out of tech and coming here.
1 · Reply
harmongreg
harmongreg Jun. 9 at 7:06 PM
added some $JNJ June 26 Expiry 240/250 call spreads
0 · Reply
TheUnmaker
TheUnmaker Jun. 9 at 6:20 PM
$TNXP $LLY $JNJ $PFE $PG Dip buyers know a good dip!
0 · Reply
HydrogenH2
HydrogenH2 Jun. 9 at 4:30 PM
$JNJ When Cramer say "Buy" you sell... when Cramer say " Sell" you buy... Well now you know !!
0 · Reply
TheUnmaker
TheUnmaker Jun. 9 at 2:08 PM
$TNXP $LLY $JNJ $PFE $PG
0 · Reply
TheUnmaker
TheUnmaker Jun. 9 at 1:13 PM
$TNXP https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-secures-second-commercial-payer-agreement-for-3hp9luv3fb7w.html $LLY $JNJ $PFE $PG
0 · Reply
ewforecast
ewforecast Jun. 9 at 7:48 AM
$JNJ Johnson & Johnson Update: Wave 4 Correction May Be Nearing Completion After Wave 3 Extension #JohnsonNJohnson #elliottwave Check it below https://wavetraders.com/free-charts/johnson-johnson-update-wave-4-correction-may-be-nearing-completion-jun-09-2026/
0 · Reply
freedomtrader6
freedomtrader6 Jun. 8 at 9:16 PM
$NOW Okay, hear me out… AI stocks are getting nuts, and maybe it’s time to park some cash in something that actually works. These four healthcare giants are my go-to: $LLY – Crushing it in obesity & diabetes $MRK – Cash-printing pharma machine $UNH – Insurance kingpin $JNJ – Diversified healthcare beast They’re not flashy, but that’s the point steady, reliable, and they make money while everyone else panics. Honestly, sometimes boring wins.
0 · Reply
notreload_ai
notreload_ai Jun. 8 at 3:15 PM
$JNJ is acquiring Firefly Bio for $1 billion to expand its cancer pipeline. The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue. https://notreload.xyz/xy/jnj-buys-firefly-bio-for-1b-to-fight-kras-cancer/
0 · Reply
BetaLaboratory
BetaLaboratory Jun. 8 at 2:08 PM
$JNJ's $1B move on Firefly Bio shows it's still willing to bet aggressively on innovation. Large pharma needs new growth engines, and biotech acquisitions remain one of the fastest ways to strengthen the pipeline and access next-generation therapies.
0 · Reply
TrendOriented
TrendOriented Jun. 8 at 1:55 PM
$OKLO Oklo just announced it is acquiring ARMEC, a precision manufacturing and engineering firm. Another step toward vertical integration in advanced nuclear and clean energy infrastructure. $JNJ Johnson & Johnson also moving, agreeing to acquire Firefly Bio for $1B, continuing its push into next-gen biotech innovation. M&A is clearly picking up again. When big players start consolidating tech and bio assets, it usually signals where the next cycle of growth is being built.
0 · Reply